Aralez Bio

Executive Summary

Aralez Bio is a San Francisco-based biotechnology company pioneering the scalable production of noncanonical amino acids (ncAAs) through a proprietary biocatalytic enzyme platform. Founded in 2021, the company addresses a critical bottleneck in advanced peptide therapeutics: the availability and cost of these specialized building blocks. Aralez's technology enables sustainable, cost-effective manufacturing with demonstrated scale-up to 100 kg batches at its Berkeley, CA facility, serving both discovery research and commercial production needs. By providing high-purity ncAAs, Aralez empowers drug developers to design peptides with enhanced stability, potency, and bioavailability, unlocking new therapeutic modalities. With the peptide therapeutics market growing rapidly, Aralez is well-positioned to capture significant value as a key supplier. The company's pre-clinical stage and focus on enabling technologies differentiate it from traditional drug developers. Key milestones include process validation at scale and early customer engagement. While still private and without disclosed funding, Aralez's technology has the potential to disrupt the supply chain for novel peptides. The company's conviction score is 70, reflecting a strong technological moat but early commercial traction. Near-term catalysts include strategic partnerships, series funding, and expansion of its product catalog to meet demand from pharma and biotech customers.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a major pharmaceutical company for ncAA supply in peptide development60% success
• Q2 2027Series A/B fundraising round to expand production capacity and R&D75% success
• Q1 2027Launch of new noncanonical amino acid product line targeting emerging peptide modalities80% success